MedTrace Logo

Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis

NCT02537210 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 177

Last updated 2023-05-31

No results posted yet for this study

Summary

The purpose of this study is to determine whether aminosalicylic acid (ASA) can be safely withdrawn in patients with long-standing clinical inactive UC.

Conditions

  • Colitis, Ulcerative
  • Aminosalicylic Acid

Interventions

DRUG

Mesalazine

Patients will be prescribed Asacol 2g daily for 12 months

DRUG

Placebo oral capsule

Patients will be prescribed placebo 5 capsules daily for 12 months

Sponsors & Collaborators

  • Queen Elizabeth Hospital, Hong Kong

    collaborator OTHER

  • Alice Ho Miu Ling Nethersole Hospital

    collaborator OTHER

  • Tseung Kwan O Hospital, Hong Kong

    collaborator OTHER

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Siew Ng, PhD · Chinese University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2021-09-10
Completion
2021-09-10

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02537210 on ClinicalTrials.gov